Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1105-1115

  Kadowaki, Masami ^a   Sangai, Takafumi ^a   Nagashima, Takeshi ^a   Sakakibara, Masahiro ^a   Yoshitomi, Hideyuki ^a   Takano, Shigetsugu ^a   Sogawa, Kazuyuki ^a   Umemura, Hiroshi ^a   Fushimi, Koya ^a   Nakatani, Yukio ^a,b   Nomura, Fumio ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Immunodepletion; Proteomics; Serum marker; Vitronectin

Indexed keywords

VITRONECTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; VITRONECTIN;

EID: 79959769545     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0974-9     Document Type: Article

References (36)

1. Aaboe M, Offersen BV, Christensen A, Andreasen PA (2003) Vitronectin in human breast carcinomas. Biochim Biophys Acta 1638:72-82 (Pubitemid 36577374)
2. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867
3. Cho W, Jung K, Regnier FE (2010) Sialylated Lewis x antigen bearing glycoproteins in human plasma. J Proteome Res 9:5960-5968
4. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48:1194-1197
5. Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. Jama 293:1245-1256 (Pubitemid 40327910)
6. Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J, Zheng S, Li M, Wang J (2010) Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol 136:1243-1254
7. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658 (Pubitemid 24245001)
8. Freeman WM, Lull ME, Guilford MT, Vrana KE (2006) Depletion of abundant proteins from non-human primate serum for biomarker studies. Proteomics 6:3109-3113
9. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
10. Hattori N, Oda S, Sadahiro T, Nakamura M, Abe R, Shinozaki K, Nomura F, Tomonaga T, Matsushita K, Kodera Y, Sogawa K, Satoh M, Hirasawa H (2009) YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 32:393-400
11. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, Huang M (2008) Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 15:422-423 (Pubitemid 351483393)
12. Jmeian Y, El Rassi Z (2009) Liquid-phase-based separation systems for depletion, prefractionation and enrichment of proteins in biological fluids for in-depth proteomics analysis. Electrophoresis 30:249-261 Review
13. Kawashima Y, Fukuno T, Satoh M, Takahashi H, Matsui T, Maeda T, Kodera Y (2009) A simple and highly reproducible method for discovering potential disease markers in low abundance serum proteins. J Electrophoresis 53:13-18
14. Kawashima Y, Fukutomi T, Tomonaga T, Takahashi H, Nomura F, Maeda T, Kodera Y (2010) High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. J Proteome Res 9:1694-1705
15. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW (2009) The multiple bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 11:R22
16. Kulasingam V, Diamandis EP (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 5:588-599
17. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
18. Liu J, Liu YG, Huang R, Yao C, Li S, Yang W, Yang D, Huang RP (2007) Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 4:377-385
19. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ (2005) Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 11:1073-1085 (Pubitemid 40175756)
20. Martosella J, Zolotarjova N, Liu H, Nicol G, Boyes BE (2005) Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 4:1522-1537 (Pubitemid 41464777)
21. Oh-Ishi M, Satoh M, Maeda T (2000) Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins. Electrophoresis 21:1653-1669 (Pubitemid 30394858)
22. Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41:40-47 (Pubitemid 40066381)
23. Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics. CA Cancer J Clin 55:74-108
24. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW (2008) Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7:1162-1173 (Pubitemid 351943962)
25. Satoh M, Haruta-Satoh E, Omori A, Oh-Ishi M, Kodera Y, Furudate S, Maeda T (2005) Effect of thyroxine on abnormal pancreatic proteomes of the hypothyroid rdw rat. Proteomics 5:1113-1124 (Pubitemid 40469039)
26. Schlesinger M, Broman I, Lugassy G (1996) The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 10:1509-1513 (Pubitemid 26290334)
27. Schmitt M, Sturmheit AS, Welk A, Schnelldorfer C, Harbeck N (2006) Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med 120:245-265
28. Søiland H, Janssen EA, Kørner H, Varhaug LE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA (2009) Apolipoprotein D predicts adverse outcome in women > or = 70 years with operable breast cancer. Breast Cancer Res Treat 113:519-528
29. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405-1410 (Pubitemid 36515039)
30. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD (2003) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096-1103
31. Umemura H, Nezu M, Kodera Y, Satoh M, Kimura A, Tomonaga T, Nomura F (2009) Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-offlight mass spectrometry. Clin Chim Acta 406:179-180
32. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G (2005) Breast cancer. Lancet 365:1727-1741 (Pubitemid 40719108)
33. Xu SG, Yan PJ, Shao ZM (2010) Differential proteomics analysis of a highly metastatic variant og human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol 136:1545-1556
34. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R, Michalopoulos G, Luo JH (2007) Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 67:8043-8050 (Pubitemid 47395138)
35. Zheng G, Peng F, Ding R, Yu Y, Ouyang Y, Chen Z, Xiao Z, He Z (2010) Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. J Cancer Res Clin Oncol 136:1477-1488
36. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC (2005) Differences among techniques for high-abundant protein depletion. Proteomics 5:3304-3313 (Pubitemid 41192037)